Objetivo
COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity.
Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide “industry-standard” cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person.
COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in “decoding” the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.
Ámbito científico
- medical and health sciencesbasic medicineneurologyepilepsy
- medical and health sciencesmedical biotechnologygenetic engineeringgene therapy
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesclinical medicinepsychiatryschizophrenia
Programa(s)
Tema(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-PHC-2015-two-stage
Régimen de financiación
RIA - Research and Innovation actionCoordinador
17177 Stockholm
Suecia
Ver en el mapa
Participantes (13)
75724 Paris
Ver en el mapa
80539 Munchen
Ver en el mapa
53127 Bonn
Ver en el mapa
CF24 0DE Cardiff
Ver en el mapa
00014 Helsingin Yliopisto
Ver en el mapa
1081 HV Amsterdam
Ver en el mapa
3400 Hillerod
Ver en el mapa
1008 BA AMSTERDAM
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
72076 Tubingen
Ver en el mapa
53127 Bonn
Ver en el mapa
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.
2500 Valby
Ver en el mapa
4070 Basel
Ver en el mapa
3761HA SOEST
Ver en el mapa